Abiopharma

🔍 Hoffmeister David F (Executive)

Company: GLAUKOS Corp (GKOS)

Report Date: 2026-01-02

Detailed Transactions and Holdings:

• Acquired 753 shares of Common Stock (Direct)
  Date: 2026-01-02 | Code: A | equity_swap_involved: 0 | shares_owned_after: 32,671.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-01-02 | Code: H | nature_of_ownership: Through Sentinel Point Partners, Inc. | shares_owned_after: 38,176.00

Footnotes:

• F1: Represents a grant of restricted stock units received by the Reporting Person pursuant to the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock.
• F2: Includes 2,861 restricted stock units that have not vested or been delivered to the Reporting Person, as well as restricted stock units that have vested but delivery of which has been deferred by the Reporting Person.